X-Linked Retinitis Pigmentosa (XLRP)
Symptoms, Doctors, Treatments, Advances & More

X-Linked Retinitis Pigmentosa (XLRP) Overview

Save information for later
Sign Up

Learn About X-Linked Retinitis Pigmentosa (XLRP)

View Main Condition: Retinitis Pigmentosa

What is the definition of X-Linked Retinitis Pigmentosa (XLRP)?
X-linked retinitis pigmentosa is a type of inherited eye disorder that affects the retina, causing progressive vision loss. X-linked retinitis pigmentosa is classified as non-syndromic because it occurs by itself instead of as part of other syndromes.
What are the symptoms of X-Linked Retinitis Pigmentosa (XLRP)?
Symptoms of X-linked retinitis pigmentosa include a loss of night vision in childhood; blind spots in the side, or peripheral, vision; tunnel vision; loss of central vision; and, eventually, blindness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for X-Linked Retinitis Pigmentosa (XLRP)?
Treatment for X-linked retinitis pigmentosa involves the use of gene therapy made from adeno-associated viral vectors.
Who are the top X-Linked Retinitis Pigmentosa (XLRP) Local Doctors?
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
City Road, 
London, ENG, GB 

Michel Michaelides practices in London, United Kingdom. Mr. Michaelides is rated as an Elite expert by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are Retinopathy Pigmentary Mental Retardation, Color Blindness, Retinitis Pigmentosa, Vitrectomy, and Cataract Removal.

Elite in X-Linked Retinitis Pigmentosa (XLRP)
Tom R. Denee
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Tom R. Denee
50-100 Holmers Farm Way, Buckinghamshire, 
High Wycombe, ENG, GB 

Tom Denee practices in High Wycombe, United Kingdom. Mr. Denee is rated as an Elite expert by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinopathy Pigmentary Mental Retardation, Retinitis Pigmentosa, and Late-Onset Retinal Degeneration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Byron Lam
Ophthalmology
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Byron Lam
Ophthalmology

Office

900 NW 17th St Ste 3, 
Miami, FL 
305-243-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Byron Lam is an Ophthalmologist in Miami, Florida. Dr. Lam is rated as an Elite provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Optic Nerve Atrophy, Vitrectomy, and Nerve Decompression.

View All Doctors
What are the latest X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials?
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Biological
Study Phase: Phase 2

Summary: The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)
Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)
Enrollment Status: Recruiting
Publish Date: January 16, 2026
Intervention Type: Genetic
Study Phase: Phase 3

Summary: The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

View All Clinical Trials